Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 5/5 core metricsLatest reported annual revenue changed -13.3% from the prior reported annual observation.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Revenue contracted
Latest reported annual revenue changed -13.3% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2026-06-30.
- Operating margin compressed
Operating margin changed -2.7 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2026-06-30.
- 2 filing risk checks flagged
Flagged areas: Solvency & liquidity.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Free cash flow turned positive
Latest reported free cash flow was $3M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2026-06-30.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Solvency & liquidity
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-11-22
- Latest period end
- 2026-06-30
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- RX Segment$57.6M100.0%-13.3% yoy
Members sum to the consolidated $57.6M for this period.
- RX Segment$12.4M100.0%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2026-06-30 · among 4,026 US-listed filers · 781 in Materials| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $58M | 22ndof 3,198 bottom third | 38thof 502 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | -13.3% | 10thof 3,041 bottom third | 19thof 456 bottom third |
Gross margin gross profit ÷ revenue | 64.0% | 80thof 1,557 top third | 85thof 213 top third |
Operating margin operating income ÷ revenue | -14.4% | 29thof 2,733 bottom third | 54thof 465 middle third |
Net margin net income ÷ revenue | -24.8% | 23rdof 3,157 bottom third | 47thof 495 middle third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | 5.7% | 53rdof 2,598 middle third | 68thof 420 top third |
Return on equity net income ÷ stockholders' equity (positive equity only) | -40.4% | 21stof 3,488 bottom third | 47thof 684 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 1.2% | 62ndof 2,809 middle third | 74thof 456 top third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 144 days | 5thof 2,340 bottom third | 10thof 374 bottom third |
Net debt ÷ operating cash flow net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher | -5.2× | 98thof 1,501 top third | 98thof 140 top third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -15.3% | 82ndof 3,803 top third | 74thof 742 top third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2026-06-30 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 25 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Net income NetIncomeLoss | quarter 2022-09-30 | -$2.88M 10-Q 2022-11-14 | -$701K 10-Q 2024-05-15 | +75.7% | first · latest · 7 filings carry it |
| Operating income OperatingIncomeLoss | fiscal year 2024-06-30 | -$5.25M 10-K 2024-09-26 | -$1.59M 10-K 2025-09-23 | +69.7% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2023-09-30 | -$1.5M 10-Q 2023-11-14 | -$867K 10-Q 2024-11-13 | +42.4% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2024-03-31 | -$2.46M 10-Q 2024-05-15 | -$1.6M 10-Q 2025-05-14 | +35.2% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2023-12-31 | $2.36M 10-Q 2024-02-14 | $3.15M 10-Q 2025-02-12 | +33.1% | first · latest |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | quarter 2024-03-31 | $18M 10-Q 2024-05-15 | $14M 10-Q 2025-05-14 | -22.1% | first · latest |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | fiscal year 2024-06-30 | $81M 10-K 2024-09-26 | $65.2M 10-K 2025-09-23 | -19.5% | first · latest |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | quarter 2023-09-30 | $22.1M 10-Q 2023-11-14 | $17.8M 10-Q 2024-11-13 | -19.4% | first · latest |
| Stock-based compensation ShareBasedCompensation | fiscal year 2024-06-30 | $2.91M 10-K 2024-09-26 | $2.37M 10-K 2025-09-23 | -18.5% | first · latest |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | quarter 2023-12-31 | $22.9M 10-Q 2024-02-14 | $18.7M 10-Q 2025-02-12 | -18.3% | first · latest |
| Gross profit GrossProfit | quarter 2023-09-30 | $14.8M 10-Q 2023-11-14 | $13M 10-Q 2024-11-13 | -11.8% | first · latest |
| Gross profit GrossProfit | quarter 2024-03-31 | $11.7M 10-Q 2024-05-15 | $10.4M 10-Q 2025-05-14 | -11.4% | first · latest |
| Stockholders' equity StockholdersEquity | balance at 2022-09-30 | $53.9M 10-Q 2022-11-14 | $48.3M 10-Q 2024-05-15 | -10.3% | first · latest · 4 filings carry it |
| Gross profit GrossProfit | fiscal year 2024-06-30 | $54.6M 10-K 2024-09-26 | $49.1M 10-K 2025-09-23 | -10.1% | first · latest |
| Gross profit GrossProfit | quarter 2023-12-31 | $16.2M 10-Q 2024-02-14 | $14.6M 10-Q 2025-02-12 | -9.9% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2022-09-30 | -$1.65M 10-Q 2022-11-14 | -$1.81M 10-Q 2023-11-14 | -9.4% | first · latest · 3 filings carry it |
| Receivables AccountsReceivableNetCurrent | balance at 2020-06-30 | $5.18M 10-K 2020-10-06 | $5.63M 10-K 2021-09-28 | +8.8% | first · latest · 5 filings carry it |
| Total liabilities Liabilities | balance at 2022-09-30 | $96.1M 10-Q 2022-11-14 | $102M 10-Q/A 2023-02-21 | +5.8% | first · latest |
| Stockholders' equity StockholdersEquity | balance at 2022-06-30 | $46.1M 10-K 2022-09-27 | $44.3M 10-K 2024-09-26 | -3.9% | first · latest · 9 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2022-03-31 | -$54.7M 10-Q 2022-05-16 | -$53.4M 10-Q 2023-05-11 | +2.3% | first · latest |
| Total liabilities Liabilities | balance at 2022-06-30 | $91.5M 10-K 2022-09-27 | $93.3M 10-K 2023-10-12 | +1.9% | first · latest · 6 filings carry it |
| Operating income OperatingIncomeLoss | fiscal year 2022-06-30 | -$112M 10-K 2022-09-27 | -$110M 10-K 2023-10-12 | +1.5% | first · latest |
| Net income NetIncomeLoss | fiscal year 2022-06-30 | -$110M 10-K 2022-09-27 | -$109M 10-K 2023-10-12 | +1.3% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2022-12-31 | -$6.79M 10-Q 2023-02-21 | -$6.87M 10-Q 2024-02-14 | -1.1% | first · latest |
| Total liabilities Liabilities | balance at 2020-06-30 | $57.8M 10-K 2020-10-06 | $58.3M 10-K 2021-09-28 | +0.8% | first · latest · 5 filings carry it |
10 share-count periods re-presented for a stock split (1-for-20) are listed apart from restatements and not counted above.
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding; share counts re-presented by an integer split ratio are listed as split adjustments, not restatements. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
debt, leases, revenue, segments, contingencies, taxes and more · the filer's own wordsCommitments and contingencies · 6,820 characters as filed
Note 18 - Commitments and Contingencies EXXUA Exclusive Commercialization Agreement On June 5, 2025, the Company, entered into the Commercialization Agreement with Fabre-Kramer, pursuant to which the Company acquired certain rights and obligations in connection with the commercialization of EXXUA in the United States. As consideration for the Commercialization Agreement, the Company made an upfront cash payment of $3.0 million to Fabre-Kramer in June 2025, which was capitalized as a definite-lived intangible asset (see Note 7 - Intangible Assets for further detail). Within 45 days of the one -year anniversary of the first product launch EXXUA in the United States, the Company has agreed to make a second $3.0 million payment (the Second Payment). The Second Payment may be increased to $5.0 million if first year EXXUA net sales meet or exceed $35.0 million. Additionally, the Company has agreed to pay Fabre-Kramer certain milestone payments ranging from $5.0 million to over $100.0 million per year based on sales milestones after a certain level of net sales are achieved with a threshold of $100.0 million in net sales and the Company will pay 10% of net sales exceeding $1.0 billion. The Company has also agreed to pay royalty fees throughout the term of the Commercialization Agreement based on the Companys net sales of EXXUA as follows: (i) initially 28% of net sales and increasing to 39% if net sales exceed $300.0 million in any year during the term until such net sales reach a r …
CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing
Revenue disaggregation · 171 characters as filed
Year Ended June 30, 2026 2025 (in thousands) EXXUA $ 6,574 $ ADHD Portfolio 45,825 57,576 Pediatric Portfolio 5,135 8,769 Other 36 37 Total net revenue $ 57,570 $ 66,382 …
DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing
Share-based compensation · 6,272 characters as filed
Note 15 - Equity Incentive Plan 2023 Equity Incentive Plan On May 18, 2023, the Companys stockholders approved the adoption of the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the 2023 Equity Incentive Plan), which replaced all previous plans. For the 2023 Equity Incentive Plan, the stockholders approved (a) 200,000 new shares; (b) 87,155 shares rolled over to the 2023 Equity Incentive Plan from plans replaced by the 2023 Equity Incentive Plan; and (c) any shares that are returned to the Company under plans replaced by the 2023 Equity Incentive Plan to be added to the 2023 Equity Incentive Plan. On May 21, 2025, the Companys stockholders approved an amendment (the Plan Amendment) to the 2023 Equity Incentive Plan. The Plan Amendment increased the number of shares reserved for issuance under the 2023 Equity Incentive Plan by 300,000 shares to bring the total number of shares reserved for issuance under the 2023 Equity Incentive Plan to 500,000 shares, not including unissued shares from available awards under prior plans or any returned shares. The Plan Amendment became effective immediately upon approval by the Companys stockholders and the Company registered the 300,000 shares pursuant to a registration statement on Form S- 8 filed with the SEC on September 23, 2025. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under any previous plan. All outstanding awards previously granted under previous stock incentive plans will remain ou …
DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing
Fair value · 5,878 characters as filed
Note 12 - Fair Value Measurements The Company determines the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to the Company for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. The Companys financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, fixed payment arrangements and current and non-current debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Current and non-current debt are reported at their amortized costs on the Companys consolidated balance sheets. The remaining financial instruments are reported on the Companys consolidated balance sheets at amounts that approximate current fair values. The Companys policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused …
FairValueDisclosuresTextBlock · excerpt; the full note is in the filing
Income taxes · 10,389 characters as filed
Note 13 - Income Taxes For the years ended June 30, 2026 , and 2025 , there was insignificant income tax expense and $0.4 million of income tax expense from continuing operations, which was an effective tax rate of negative 0.1% and negative 3.2%, respectively. This income tax expense was primarily driven by Section 382 limitation of the IRC on pre-Tax Cuts and Jobs Act (the TCJA) and post-TCJA net operating loss (NOL) utilization, as further described below, coupled with existing valuation allowances. As of June 30, 2026 , and 2025 , the Company had $0.2 million and $0.3 million of deferred tax assets (DTAs), net of valuation allowance from continuing operations, respectively, included in other non-current assets and $0.2 million and $0.3 million of deferred tax liabilities (DTLs) from continuing operations, respectively, included in other non-current liabilities. As of June 30, 2026 , and 2025 , the Company had $1.3 million and $1.1 million of prepaid income taxes included in prepaid expenses and other current assets recorded in the Company's consolidated balance sheets. Section 382 Limitation Under the provisions of the IRC, substantial changes in the Companys ownership have resulted in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is li …
IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing
Long-term debt · 4,253 characters as filed
Note 11 - Debt On June 20, 2025, the Company and certain of its subsidiaries entered into Eclipse Amendment No. 6, which provided for among other things, an increase in the Eclipse Term Loan principal amount of $13.0 million on the closing date of the Eclipse Amendment No. 6 and an extension of the maturity date of the Eclipse Term Loan to June 12, 2029, as well as certain amendments to the Eclipse Revolving Loan described further in Note 10 - Revolving Credit Facility . The Eclipse Term Loan incurs interest at a rate of the SOFR plus 7.0%, with a four -year term maturing, as amended, on June 12, 2029, and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four -year term of $5.6 million to be repaid on the maturity date of June 12, 2029. The Company used proceeds from the Eclipse Term Loan and a portion of the proceeds from the exercise of warrants to repay a $15.0 million term loan in full. In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Eclipse Term Loan if such event occurs after June 12, 2026, but on or before June 12, 2027, ( ii) 1.0% of the Eclipse Term Loan if such event occurs after June 12, 2027, but on or before June 12, 2028, and (iii) 0.5% of the Eclipse Term Loan if such eve …
LongTermDebtTextBlock · excerpt; the full note is in the filing
New accounting pronouncements · 3,410 characters as filed
Recent Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU No. 2024 - 03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220 - 40 ): Disaggregation of Income Statement Expenses (ASU 2024 - 03 ). The amendments in ASU 2024 - 03 require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024 - 03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Companys consolidated financial statements and disclosures. In December 2025, the FASB issued ASU 2025 - 10, Government Grants (Topic 832 ): Accounting for Government Grants Received by Business Entities (ASU 2025 - 10 ), to provide guidance on how business entities should recognize, measure, and present government grants received. ASU 2025 - 10 is effecti …
NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing
Restructuring · 1,594 characters as filed
Note 17 - Restructuring Costs As part of the Companys previously announced restructuring activities related to the wind down and divestiture of the Consumer Health business and the closure of the Grand Prairie, Texas manufacturing site, the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance. Restructuring costs associated with the Consumer Health business are recorded within the net income (loss) from discontinued operations, net of tax in the consolidated financial statement of operations (see Note 20 - Discontinued Operations ). The expense associated with the closure of the Grand Prairie, Texas manufacturing site such as severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations. There have been no inventory write-downs associated with this closure. No such costs were incurred during the year ended June 30, 2026. During the years ended June 30, 2025, the Company incurred $2.1 million of costs associated with exit and disposal activities related to its previously announced operational realignment and re …
RestructuringAndRelatedActivitiesDisclosureTextBlock · excerpt; the full note is in the filing
Revenue recognition · 1,093 characters as filed
Note 3 - Revenue The Company disaggregates its net revenue from continuing operations by product portfolio, which for the years ended June 30, 2026 , and 2025 , includes EXXUA; the ADHD Portfolio, comprised primarily of Adzenys and Cotempla; and the Pediatric Portfolio, comprised primarily of Karbinal. The Companys disaggregation of revenue is consistent with its operating segment. Net Revenue by Product Portfolio Net revenue disaggregated by product portfolios for the years ended June 30, 2026 , and 2025 , were as follows: Year Ended June 30, 2026 2025 (in thousands) EXXUA $ 6,574 $ ADHD Portfolio 45,825 57,576 Pediatric Portfolio 5,135 8,769 Other 36 37 Total net revenue $ 57,570 $ 66,382 Other includes net revenue from various discontinued or deprioritized products. The Consumer Health business was divested in the first quarter of fiscal 2025 and is reported within discontinued operations (see Note 20 - Discontinued Operations ). Net Revenue by Geographic Location The Companys net revenue is predominately within the United States, with insignificant international sales. …
RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing
Significant accounting policies · 32,110 characters as filed
Note 2 - Summary of Significant Accounting Policies Principles of Consolidation The Companys consolidated financial statements and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. (Neos) and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. (Innovus) and its wholly owned subsidiaries prior to the divestiture of Innovus on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation. Basis of Presentation The Companys consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). Use of Estimates The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (ROU) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; depreciable lives of lo …
SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing
Stockholders' equity · 1,854 characters as filed
Note 14 - Stockholders Equity The Company has 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share and no preferred shares issued and outstanding. The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and as of September 15, 2026 , June 30, 2026 , and June 30, 2025 , the Company had 10,866,708, 10,728,208 and 8,976,913 shares of common stock issued and outstanding, respectively. As of June 30, 2026 , included in common stock outstanding are 213,083 shares of unvested restricted stock issued to directors, executives and employees. On September 26, 2024, the Company filed a shelf registration statement on Form S- 3, which was declared effective by the SEC on October 15, 2024. This shelf registration statement covers the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the 2024 Shelf). Through the filing date of this report, $100.0 million remains available under the 2024 Shelf. This availability is subject to the SECs baby shelf limitation as set forth in SEC Instruction I.B.6 limitation to the Form S- 3. In June 2025, the Company raised gross proceeds of $16.6 million from the issuance of (i) 2,806,668 shares of its common stock, at a public offering price of $1.50 (the June 2025 Common Stock), and 8,233,332 prefunded warrants at a public offering price of $1.4999 to purchase 8,23 …
StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing
Subsequent events · 1,302 characters as filed
Note 21 - Subsequent Events The Company evaluated subsequent events for potential recognition or disclosure in the consolidated financial statements through September 22, 2026 , the date the consolidated financial statements were issued and included in this Annual Report on Form 10 -K. Other than the matters described below and elsewhere in this Annual Report, the Company concluded that there were no subsequent events requiring recognition or disclosure in the consolidated financial statements. Cotempla Authorized Generic Pursuant to the Company's license agreement with Teva, Teva's right to manufacture and market an authorized generic version of Cotempla commenced on July 1, 2026 ( see Note 19 - License Agreements for further detail). The Company is unable to estimate the financial effect on future net revenue at this time. Eclipse Incremental Advance In July 2026, the Company repaid in full the remaining $0.1 million outstanding balance of the Eclipse Incremental Advance under the Eclipse Revolving Loan (see Note 10 - Revolving Credit Facility for further detail). No other events have occurred subsequent to June 30, 2026 , and through the issuance date of these consolidated financial statements that would require recognition or disclosure in the consolidated financial statements.
SubsequentEventsTextBlock
Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.